Skip to main content
. 2017 May 11;8(26):42997–43007. doi: 10.18632/oncotarget.17792

Figure 5. CED of [225Ac]Pep-1L in vivo shows significantly greater efficacy compared to control groups.

Figure 5

Kaplan-Meier curve showing significantly greater overall survival, median survival and mean survival (p < 0.05) of mice treated with [225Ac]Pep-1L when compared to mice in control group. Efficacy of [225Ac]Pep-1L against orthotopic GBMs when infused via CED is demonstrated by the greater overall survival, median survival and mean survival.